Baseline Steroid Use Significantly Reduces Immune Checkpoint Inhibitor Effectiveness in NSCLC Patients
核心洞察
A study of 277 NSCLC patients found that baseline corticosteroid use was the strongest independent predictor of disease progression and mortality during immune checkpoint inhibitor therapy.
Patients taking steroids at treatment initiation experienced significantly lower response rates and shorter progression-free survival compared to those not receiving steroids.
Steroid use disrupted blood-based immune biomarkers, reducing circulating CX3CR1 (搜索)+ CD8+ T cells and making neutrophil-to-lymphocyte ratio less reliable as a prognostic indicator.
A comprehensive study involving 277 patients with non-small cell lung cancer (NSCLC) has revealed that baseline corticosteroid use significantly compromises the effectiveness of immune checkpoint inhibitor (ICI) therapy, emerging as the strongest independent predictor of treatment failure and mortality.
The research, published in Cancer Research Communications and led by Dr. Fumito Ito from the University of Southern California, analyzed patients treated at Roswell Park Comprehensive Cancer Center and USC Norris Comprehensive Cancer Center between October 2013 and August 2023. Only 8% of patients were taking steroids at treatment initiation, but this small subset experienced dramatically worse outcomes.
Clinical Impact on Treatment Outcomes
Patients receiving baseline steroids demonstrated significantly lower overall response rates at both institutions (P = 0.0141 at RPCCC; P = 0.0454 at USC). The survival differences were striking: median progression-free survival was reduced from 10.7 months to 3.2 months at RPCCC and from 6.6 months to 3.0 months at USC for steroid users versus non-users, respectively.
Overall survival showed similar patterns, with steroid users experiencing median survival of 7.7 months at RPCCC and 3.7 months at USC, compared to 21.0 months and 16.4 months for non-steroid users. Multivariate analysis confirmed that steroid use was the only significant independent risk factor for disease progression and mortality across both cohorts.
"Steroids were the biggest predictor of why certain immunotherapies may not be effective, even when considering multiple other factors such as stage and progression of the disease," Dr. Ito explained. The study found that steroid use was a more influential prognostic factor than even the presence of brain metastases.
Biomarker Disruption and Immune System Impact
The research revealed that baseline steroid use significantly disrupted blood-based immune markers used to predict treatment response. Patients taking steroids had notably lower levels of CX3CR1 (搜索)+ CD8+ T cells, which help signal how effectively the immune system is fighting cancer.
Additionally, while a neutrophil-to-lymphocyte ratio below 5 typically serves as a strong prognostic indicator for ICI therapy, this relationship was completely absent in patients receiving steroids, complicating clinical decision-making and treatment monitoring.
Mechanistic Insights from Preclinical Studies
To understand the underlying mechanisms, researchers conducted parallel studies using anti-PD-L1 (搜索) therapy in tumor-bearing mice with and without steroid exposure. The preclinical work demonstrated that steroids blunted the therapeutic benefit of anti-PD-L1 therapy and limited T-cell development.
"Our findings reveal that steroids stop the body's natural cancer-fighting cells, T-cells, from maturing. This makes them unable to attack the cancer as vigorously as they usually would, leading to worse outcomes for patients," Dr. Ito noted.
Dose-Dependent Effects and Treatment Timing
The study identified a dose-dependent relationship, with higher baseline steroid doses associated with progressively worse patient outcomes. Importantly, patients who discontinued steroids before initiating ICI therapy achieved better outcomes than those who continued steroid treatment.
However, even when steroids were discontinued before treatment, prior exposure still appeared to compromise the reliability of immune biomarkers, suggesting lasting effects on immune system function.
Clinical Implications for Patient Management
Among the 21 patients receiving steroids in the study, the primary indications were brain metastases (80%) and comorbid lung conditions such as chronic obstructive pulmonary disease (20%). All patients had remained on steroids for at least 12 weeks after initiating ICI therapy.
The findings have significant implications for clinical practice, as corticosteroids are frequently prescribed to manage lung cancer symptoms. While the study authors acknowledged limitations including the small number of steroid users and incomplete biomarker data for some participants, they emphasized that the results support efforts to reduce steroid use before starting ICI treatment.
"Without the presence of circulating biomarkers to inform our decisions, oncologists cannot treat the cancer as effectively, and patients may miss out on the best treatment for their cancer," Dr. Ito explained. "We know that steroids will continue to play an important role in lung cancer care, but it is important to understand their potential limitations."
The research provides crucial evidence for oncologists to consider when developing treatment plans, particularly for the approximately 87% of lung cancer patients diagnosed with NSCLC, where the five-year survival rate remains around 32% for patients diagnosed between 2015 and 2021.